Article
Dentistry, Oral Surgery & Medicine
Jie Liu, Nikos Mattheos, Chuanxi Deng, Cheng Su, Zekun Wang, Nanyu Luo, Hua Tang
Summary: Icariin benefits MRONJ by improving soft tissue wound area and empty bone lacuna ratio, while teriparatide activates RANKL expression and reduces bone necrosis area and empty lacuna ratio. These findings suggest potential therapeutic benefits for patients with MRONJ.
JOURNAL OF PERIODONTOLOGY
(2021)
Article
Pharmacology & Pharmacy
Kirti Chopra, Namrita Malhan
Summary: MRONJ is a painful and intractable disease of the jaw with no established effective treatment, however, teriparatide may play an important role in the treatment with good efficacy.
AMERICAN JOURNAL OF THERAPEUTICS
(2021)
Review
Cell Biology
Fernando Jose Rascon-Ramirez, Noelia Esteban-Garcia, Juan Antonio Barcia, Albert Trondin, Cristina Nombela, Leyre Sanchez-Sanchez-Rojas
Summary: Clinical trials of cell therapies targeting stroke have shown significant growth in recent years, mainly focusing on phases I and II. Most published studies indicate that stem cells are safe to use via various routes of administration, with transient and mild adverse events that do not generally have severe consequences for health. However, there is considerable variation in statistical design, sample size, cell types, routes of administration, and functional assessments among these trials, making comparison difficult. Establishing a standardized criteria for these clinical trials will be essential for future studies to ensure favorable and reliable results.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Chemistry, Multidisciplinary
Roberto Sacco, Monica Diuana Calasans-Maia, Julian Woolley, Oladapo Akintola, Carlos Fernando de Almeida Barros Mourao, Vittorio Moraschini, Evgeny Kushnerev, Alessandro Acocella, Olamide Obisesan, Julian Yates
Summary: This umbrella review analyzed available interventional and non-interventional systematic reviews on medication-related osteonecrosis of the jaw (MRONJ) and found that the knowledge base for MRONJ in the past 20 years is weak. The review highlighted widespread low-quality studies and many poorly designed reviews in this area.
APPLIED SCIENCES-BASEL
(2021)
Review
Endocrinology & Metabolism
L. dos Santos Ferreira, L. G. Abreu, C. B. Calderipe, M. D. Martins, L. F. Schuch, A. C. U. Vasconcelos
Summary: The study aimed to integrate data on the use of TPTD for MRONJ cases, finding that TPTD in combination with another therapy, especially antibiotic therapy, can be considered an effective protocol for MRONJ.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Medicine, Research & Experimental
Chenhang Yu, Xinyang Hu, Qingang Hu, Yongbin Mou, Liang Ding
Summary: Medication-related osteonecrosis of the jaw is a significant side effect of certain drugs, but synthetic derivative of parathyroid hormone, Teriparatide, has shown potential in reducing its incidence through modulation of various signaling pathways.
MEDICAL HYPOTHESES
(2023)
Article
Dentistry, Oral Surgery & Medicine
Kang-Min Kim, Sehyang Kim, Hyun Hwang, Hey-Yun Kim, Dohyun Kim, Jung-Hyun Park, HyeRan Choo, Jin-Woo Kim
Summary: This case-control study examined the therapeutic effects of daily or weekly administration of teriparatide in the management of medication-related osteonecrosis of the jaw (MRONJ). The results showed that both daily and weekly injection groups had significantly faster healing compared to the control groups. Complete resolution of MRONJ was more likely in participants who received teriparatide injections.
Review
Medicine, General & Internal
Alejandro Lorenzo-Pouso, Jose Bagan, Leticia Bagan, Pilar Gandara-Vila, Cintia M. Chamorro-Petronacci, Pablo Castelo-Baz, Andres Blanco-Carrion, Maria Angeles Blanco-Fernandez, Oscar Alvarez-Calderon, Javier Carballo, Mario Perez-Sayans
Summary: This manuscript critically reviewed the medication-related osteonecrosis of the jaw (MRONJ), updating key terminology, concepts, and current trends in prevention and diagnosis, while examining therapeutic options available. By perusing relevant literature, the review updated the understanding of MRONJ, highlighting gaps in knowledge and emphasizing the need for further research.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Chemistry, Multidisciplinary
Krzysztof Wrobel, Maciej Sikora, Maciej Checinski, Maria Jas, Dariusz Chlubek
Summary: MRONJ is a condition that is becoming more common in dental and maxillofacial practice, requiring comprehensive, accessible, and up-to-date data. Besides bisphosphonates, angiogenesis inhibitors and anti-RANKL monoclonal antibodies can also increase the risk of the disease. Thorough physical examination, periodic correction of dental prostheses, and adequate preparation for oral procedures can prevent or minimize the risk of MRONJ.
APPLIED SCIENCES-BASEL
(2021)
Review
Medicine, General & Internal
Isti Rahayu Suryani, Iraj Ahmadzai, Minh Ton That, Sohaib Shujaat, Reinhilde Jacobs
Summary: This systematic review assessed the potential influence of medication-induced salivary changes on the development of medication-related osteonecrosis of the jaw (MRONJ). The results showed that decreased salivary flow and changes in salivary protein concentration were associated with the occurrence of MRONJ. However, due to limited evidence, these findings should be interpreted with caution.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Gabor Kammerhofer, Daniel Vegh, Dorottya Banyai, Adam Vegh, Arpad Joob-Fancsaly, Peter Hermann, Zoltan Geczi, Tamas Hegedus, Kata Sara Somogyi, Bulcsu Bencze, Zita Biczo, Donat Huba Juhasz, Peter Zaborszky, Marta Ujpal, Mihaly Tamas Vaszilko, Zsolt Nemeth
Summary: This study aimed to evaluate the association between hyperglycemia and medication-related osteonecrosis of the jaw (MRONJ). The results showed a significant association between hyperglycemia and MRONJ, suggesting that hyperglycemia may lead to vascular anomaly and immune dysfunction, resulting in necrosis after tooth extraction.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Ilaria Roato, Rodolfo Mauceri, Vincenzo Notaro, Tullio Genova, Vittorio Fusco, Federico Mussano
Summary: The pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) involves various factors, and antiresorptive drugs (ARDs), such as bisphosphonates (BPs) and denosumab (Dmab), play a significant role in its development. The time exposure, cumulative dose, and administration intensity of these drugs are crucial in the treatment of patients, particularly cancer patients who have the highest incidence of MRONJ. BPs and Dmab have different mechanisms of action on bone and immune subsets, which ultimately contribute to the onset of MRONJ. However, there is a lack of data on the effects of Dmab, highlighting the need for further studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Ioannis Gkouveris, Akrivoula Soundia, Panagiotis Gouveris, Dionysia Zouki, Danny Hadaya, Sotirios Tetradis
Summary: Medication-related Osteonecrosis of the Jaw (MRONJ) is a significant complication of antiresorptive medications used in the management of bone diseases. Studies have shown that these medications may affect immune system components, particularly macrophages, and their involvement in the pathogenesis of MRONJ. Understanding the role of macrophages in MRONJ pathophysiology could lead to new insights for disease prevention and control.
Review
Immunology
Weidong Zhang, Ling Gao, Wenhao Ren, Shaoming Li, Jingjing Zheng, Shasha Li, Chunmiao Jiang, Shuying Yang, Keqian Zhi
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect, with hypotheses involving reduced bone remodeling, infection, inflammation, and bisphosphonates-induced immune dysfunction. Treatment with bisphosphonates disrupts mucosal and osteo immune homeostasis, impairing the body's ability to resist infection and repair from injury, contributing to the development of MRONJ.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Nutrition & Dietetics
Luca Dalle Carbonare, Monica Mottes, Maria Teresa Valenti
Summary: Osteonecrosis of the jaw is a severe clinical condition characterized by exposed bone that does not heal over time. Diagnosis is primarily clinical with imaging feedback playing a confirmatory role. Medication-related osteonecrosis of the jaw, particularly induced by bisphosphonates, has been widely discussed, but the exact mechanism remains debatable.
